Non-Hodgkin's lymphomas.
The non-Hodgkin's lymphomas, although sharing a common origin, often present physicians with wide variations in natural history and prognosis. The proper therapy of these diseases is based on an understanding of these differences and upon the information gained by pathologic review and staging, as well as the available chemotherapeutic and radiotherapeutic options.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D008223:Lymphoma / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology / Q000473:pathology* / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D009367:Neoplasm Staging / Q000379:methods; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014916:Whole-Body Irradiation
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone